Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database

Management guidelines for Lynch syndrome may require revision in light of these different gene and gender-specific risks and the good prognosis for the most commonly associated cancers.

The National(UK) Lynch Programme supported by 40tude

Most people with Lynch syndrome are well, but someone with LS has a 40-70% chance of developing colon cancer, and women also have a similar risk of cancer of the womb.  All those with LS have an increased risk of many other types of cancer.   The genetic mutations which cause Lynch Syndrome can be passed on from one generation to the next, with a 50% risk of a child inheriting this condition.

The programme has four main aims:

1) Effective diagnosis and identification of people with LS in the UK

2) Improve understanding of the biological mechanism of cancer development of people with LS

3) Develop additional tests which facilitate the prevention and early diagnosis of cancer in people with LS

4) Reduction in the variation of – and improvement in access to – care for people with LS in the UK

Immunotherapy and colorectal cancer: Where we are and what’s ahead….–where-we-are-and-what-is-ahead.h00-159459267.html?fbclid=IwAR2Eqi2DvGoFFYJ6iQvshnR_rFPuAm_AaHTgiQpWj8ebDwYd6SQc_Sd8f4Q

“To the immune system, foreign pathogens look very different from normal cells. But the difference with cancer cells isn’t as clear – except in microsatellite instability -high disease.

“Patients with MSI-high colorectal cancer are more likely to have their immune systems detect the tumors are different from normal tissue,” Kopetz says.

This helps lay the groundwork for immunotherapy to be effective. “The good news is the immune cells often recognize the cancer cells as different,” Kopetz says. “The barrier is the checkpoints – or the signals – that the tumor cells put on their surface to prevent the immune cells from attacking.”

This is where immune checkpoint inhibitors come in. They block the signal from the tumor cells that prevents the T cells from doing their work.  

Unfortunately, only 3% of patients with metastatic colorectal cancer have MSI-high disease.

“It’s very low,” Kopetz says. “But for the first time, there’s a subset of patients where we can say, ‘Despite having metastatic disease, we can cure you with immunotherapy.’” He says that hasn’t been possible with chemotherapy and targeted therapies.

%d bloggers like this: